Is Moderna (MRNA) Stock Still Worth Buying After Its Huge Rally? JPMorgan Says Yes

TipRanks2020-07-15

Shares of vaccine maker Moderna (MRNA), a $26.5 billion company that lost half a billion dollars over the past year on sales of barely $50 million, are up more than four times from the $18-and-change ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2051235277?lang=zh_CN&edition=full","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tZzTRVZbZ93HzyW44MObNQ--~B/aD00NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en-US/tipranks_452/be1a2c16defdcfb39e225ee200dd6be9","is_english":true,"pubTime":"2020-07-15 22:13","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2051235277","market":"us","top_or_hot":-1,"title":"Is Moderna (MRNA) Stock Still Worth Buying After Its Huge Rally? JPMorgan Says Yes","media":"TipRanks","content":"<div>\n<p>Shares of vaccine maker Moderna (MRNA), a $26.5 billion company that lost half a billion dollars over the past year on sales of barely $50 million, are up more than four times from the $18-and-change ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-mrna-stock-still-worth-141353390.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Moderna (MRNA) Stock Still Worth Buying After Its Huge Rally? JPMorgan Says Yes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Moderna (MRNA) Stock Still Worth Buying After Its Huge Rally? JPMorgan Says Yes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-07-15 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-mrna-stock-still-worth-141353390.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of vaccine maker Moderna (MRNA), a $26.5 billion company that lost half a billion dollars over the past year on sales of barely $50 million, are up more than four times from the $18-and-change ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-mrna-stock-still-worth-141353390.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JPM","symbol_name":"摩根大通","start_time":0,"source_url":"https://finance.yahoo.com/news/moderna-mrna-stock-still-worth-141353390.html","article_id":"2051235277","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tZzTRVZbZ93HzyW44MObNQ--~B/aD00NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en-US/tipranks_452/be1a2c16defdcfb39e225ee200dd6be9"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/moderna-mrna-stock-still-worth-141353390.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2051235277","pubTimestamp":1594822433,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of vaccine maker Moderna (MRNA), a $26.5 billion company that lost half a billion dollars ove","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JPM":"摩根大通","MRNA":"Moderna, Inc."},"translate_title":"Moderna(MRNA)股票在大幅上涨后是否还值得买入？ 摩根大通说是","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JPM":1,"MRNA":1},"content_text":"Shares of vaccine maker Moderna (MRNA), a $26.5 billion company that lost half a billion dollars over the past year on sales of barely $50 million, are up more than four times from the $18-and-change price they sold for back at the beginning of the coronavirus crisis five months ago. And profits or no profits, they're likely to go up a lot more today because of an announcement Moderna made after close of trading Tuesday.Releasing an \"interim analysis\" of the results from a Phase 1 study of its mRNA-1273 vaccine against COVID-19 Tuesday evening, Moderna confirmed that the results now appear to be fully as good as they appeared to be when preliminarily released two months ago.\"Neutralizing antibody titers were observed in 100% of evaluated participants\" regardless of whether they were given 250, 100, or only 25 micrograms (µg). The vaccine was found to be \"generally safe and well-tolerated\" among patients who received it, in two injections given 28 days apart. What's more, patients dosed with 100 µg, the level selected for a Phase 3 trial of the vaccine set to begin on July 27, were found to have, on average, more antibodies in their blood than most patients fully-recovered from infection with the novel coronavirus. In short, Moderna's mRNA-1273 vaccine \"induced rapid and strong immune responses against SARS-CoV-2.\"Side effects of mRNA-1273 were most commonly experienced by patients taking the second dose, and were generally moderate to mild in severity. About 80% of patients experienced fatigue, chills, or both after their second shot. About 60% of patients got headaches, and about 53% experienced myalgia (i.e. general muscle soreness). All patients -- 100% -- experienced some pain at the injection site, but none of these side effects were deemed sufficient to raise concern at the National Institute of Allergy and Infectious Diseases (NIAID -- Dr. Fauci's outfit), which led the clinical trial.Thus, the Phase 3 trial is still expected to get underway on July 27, with as many as 30,000 participants taking the vaccine. (The Phase 2 trial, incidentally, is already underway and fully enrolled). Moderna says it has already produced sufficient doses of the vaccine to treat all 30,000 participants in the Phase 3 trial -- and if all goes well, to then ramp up and produce anywhere from 500 million to 1 billion doses per year.Responding to this report, analyst Cory Kasimov at JPMorgan was quick to double down and re-endorse Moderna stock for investment at an \"overweight\" level. (To watch Kasimov's track record, click here)\"We are encouraged by the much anticipated detailed results from the Phase 1 study,\" said Kasimov, noting that mRNA-1273's \"ability to demonstrate neutralizing antibodies in 100% of patients across dose levels adds to the probability of ultimate success.\"Kasimov does caution that some questions still remain to be answered, in particular how well the production of antibodies translates into clinical benefits for patients.And a perhaps more important concern for investors is this: Despite retaining his overweight rating on Moderna, Kasimov still has only a $60 price target on the stock, which now worth cost more than $80 a share.Turning now to the rest of the Street, MRNA has received a total of 14 Buy recommendations and 2 Holds, making the consensus rating a Strong Buy. The $92.54 average price target brings the upside potential to 12%. (See MRNA stock analysis on TipRanks)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.2","shortVersion":"4.25.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2051235277"}